1. Home
  2. SCYX vs ANTX Comparison

SCYX vs ANTX Comparison

Compare SCYX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • ANTX
  • Stock Information
  • Founded
  • SCYX 1999
  • ANTX 2017
  • Country
  • SCYX United States
  • ANTX United States
  • Employees
  • SCYX N/A
  • ANTX N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCYX Health Care
  • ANTX Health Care
  • Exchange
  • SCYX Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • SCYX 28.5M
  • ANTX 33.2M
  • IPO Year
  • SCYX 2014
  • ANTX 2022
  • Fundamental
  • Price
  • SCYX $0.70
  • ANTX $1.07
  • Analyst Decision
  • SCYX
  • ANTX Buy
  • Analyst Count
  • SCYX 0
  • ANTX 2
  • Target Price
  • SCYX N/A
  • ANTX $2.00
  • AVG Volume (30 Days)
  • SCYX 187.5K
  • ANTX 71.9K
  • Earning Date
  • SCYX 08-11-2025
  • ANTX 08-12-2025
  • Dividend Yield
  • SCYX N/A
  • ANTX N/A
  • EPS Growth
  • SCYX N/A
  • ANTX N/A
  • EPS
  • SCYX N/A
  • ANTX N/A
  • Revenue
  • SCYX $2,630,000.00
  • ANTX N/A
  • Revenue This Year
  • SCYX $410.22
  • ANTX N/A
  • Revenue Next Year
  • SCYX $248.83
  • ANTX N/A
  • P/E Ratio
  • SCYX N/A
  • ANTX N/A
  • Revenue Growth
  • SCYX N/A
  • ANTX N/A
  • 52 Week Low
  • SCYX $0.66
  • ANTX $0.87
  • 52 Week High
  • SCYX $2.21
  • ANTX $2.73
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 41.70
  • ANTX 45.56
  • Support Level
  • SCYX $0.67
  • ANTX $1.05
  • Resistance Level
  • SCYX $0.74
  • ANTX $1.16
  • Average True Range (ATR)
  • SCYX 0.04
  • ANTX 0.03
  • MACD
  • SCYX 0.00
  • ANTX 0.00
  • Stochastic Oscillator
  • SCYX 10.15
  • ANTX 18.87

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Share on Social Networks: